Sugi Predict

Sugi Predict / Targets / DDR2

DDR2

Discoidin domain-containing receptor 2 · Q16832 · DDR2 on Sugi Atlas →

48,164 patent compounds predicted against DDR2, 36,081 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL101178 SCHEMBL101178 0.51 7/20
SCHEMBL46677 SCHEMBL46677 0.37 7/20
SCHEMBL171246 SCHEMBL171246 0.86 5/20
SCHEMBL171241 SCHEMBL171241 0.77 5/20
SCHEMBL170965 SCHEMBL170965 0.73 5/20
SCHEMBL169278 SCHEMBL169278 0.71 5/20
SCHEMBL169159 SCHEMBL169159 0.71 5/20
SCHEMBL171330 SCHEMBL171330 0.71 5/20
SCHEMBL171280 SCHEMBL171280 0.71 5/20
SCHEMBL171217 SCHEMBL171217 0.70 5/20
SCHEMBL171021 SCHEMBL171021 0.65 5/20
SCHEMBL171377 SCHEMBL171377 0.65 5/20
SCHEMBL169170 SCHEMBL169170 0.65 5/20
SCHEMBL171186 SCHEMBL171186 0.65 5/20
SCHEMBL171181 SCHEMBL171181 0.64 5/20
SCHEMBL171214 SCHEMBL171214 0.60 5/20
SCHEMBL171326 SCHEMBL171326 0.59 5/20
SCHEMBL171041 SCHEMBL171041 0.58 5/20
SCHEMBL171157 SCHEMBL171157 0.56 5/20
SCHEMBL171263 SCHEMBL171263 0.56 5/20

Clinical trials — most relevant to DDR2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
GH, IGF-I and Somatostatin Analogues in Hepatocellular Carcinoma PHASE2/PHASE3COMPLETED
Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency PHASE2/PHASE3RECRUITING
Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations PHASE2COMPLETED
Imatinib in Dermatofibrosarcoma Protuberans (DFSP) PHASE1/PHASE2COMPLETED
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs) PHASE2RECRUITING
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma PHASE2RECRUITING
Rechallenge With Panitumumab Driven by RAS Dynamic of Resistance PHASE2COMPLETED
Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer PHASE1/PHASE2COMPLETED
Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer PHASE1COMPLETED
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies PHASE1COMPLETED
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial PHASE1RECRUITING
Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers PHASE1RECRUITING
TGW211 for Click-Cleavable Imaging in HER2-Positive Cancers. EARLY_PHASE1RECRUITING
Clinical Application of 68Ga-1A12 PET in Fibrosis-related Diseases nanNOT_YET_RECRUITING
Clinical Study on the Application of PET Probes Targeting DDR2 in the Diagnosis of Interstitial Lung Disease With Cognitive Impairment nanNOT_YET_RECRUITING
Prognostic Biomarkers in Patients With Urothelial Carcinoma nanCOMPLETED
Biomarkers in Tumor Tissue Samples From Younger Patients With Rhabdomyosarcoma nanCOMPLETED
Study on the Mechanism of ADC Drug Evaluation Based on Immune Co-culture of Lung Cancer Organoids nanRECRUITING
Precision Diagnosis and Therapy for Rare Diseases by Interpreting Non-coding Genomes nanRECRUITING
Genetic of SportS Induced Endofibrotic Remodeling nanCOMPLETED
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients nanCOMPLETED
Prospective Monocentric Clinical-biological Database nanRECRUITING
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients nanRECRUITING
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Circulating Tumor DNA (ctDNA) as a Prognostic Tool in Patients With Advanced Lung Adenocarcinoma nanUNKNOWN
A Possible Founding PKD2 Mutation Associated With Variable Phenotypes of ADPKD in Bergamo Province nanCOMPLETED
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a DDR2 binder may also engage these)

ProteinNameSimilarity
Q62371 — 1.000 Q62371 →
Q60629 — 0.997 Q60629 →
Q95ZV7 — 0.994 Q95ZV7 →
EPHA3 Ephrin type-A receptor 3 0.992 landscape →
Q90344 — 0.991 Q90344 →
Q9V6K3 — 0.991 Q9V6K3 →
P54757 — 0.990 P54757 →
EPHA6 Ephrin type-A receptor 6 0.990 landscape →
Q18163 — 0.990 Q18163 →
Q03145 — 0.990 Q03145 →
Q8AXC7 — 0.990 Q8AXC7 →
Q61006 — 0.990 Q61006 →
Q07498 — 0.990 Q07498 →
O42127 — 0.989 O42127 →
EPHA5 Ephrin type-A receptor 5 0.989 landscape →
Q62838 — 0.989 Q62838 →
O42422 — 0.989 O42422 →
Q62413 — 0.989 Q62413 →
P54755 — 0.989 P54755 →
Q07497 — 0.989 Q07497 →
O13147 — 0.989 O13147 →
Q91287 — 0.988 Q91287 →
P26619 — 0.988 P26619 →
O08680 — 0.988 O08680 →
P70600 — 0.988 P70600 →
BMPR1B Bone morphogenetic protein receptor type-1B 0.988 landscape →
Q91735 — 0.988 Q91735 →
P22182 — 0.987 P22182 →
EPHB2 Ephrin type-B receptor 2 0.987 landscape →
Q91285 — 0.987 Q91285 →